[
  {
    "ts": "2026-02-25T05:46:25+00:00",
    "headline": "Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow",
    "summary": "Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.",
    "url": "https://finance.yahoo.com/news/earnings-watch-viatris-vtrs-reports-054625162.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "8498a17f-46f5-37a7-a979-23a072f9a35c",
      "content": {
        "id": "8498a17f-46f5-37a7-a979-23a072f9a35c",
        "contentType": "STORY",
        "title": "Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow",
        "description": "",
        "summary": "Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.",
        "pubDate": "2026-02-25T05:46:25Z",
        "displayTime": "2026-02-25T05:46:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VTRS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZ5PSZg5aKFn_8IHve8fGQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bPZw8EZ18ugKQPfipbnLw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/earnings-watch-viatris-vtrs-reports-054625162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earnings-watch-viatris-vtrs-reports-054625162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T11:59:00+00:00",
    "headline": "FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026. Presbyopia is the age-related progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain. The condition affects a",
    "url": "https://finance.yahoo.com/news/fda-accepts-viatris-supplemental-drug-115900299.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b5d988b5-240c-39d2-abba-6e0ca9797869",
      "content": {
        "id": "b5d988b5-240c-39d2-abba-6e0ca9797869",
        "contentType": "STORY",
        "title": "FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026. Presbyopia is the age-related progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain. The condition affects a",
        "pubDate": "2026-02-25T11:59:00Z",
        "displayTime": "2026-02-25T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8X7v9Q2NGJ8HikeN5BEPA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g4h5fNpHKz3PzdbDqFxRYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-accepts-viatris-supplemental-drug-115900299.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-accepts-viatris-supplemental-drug-115900299.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]